What is Kopin's medical — revenue?

Kopin (KOPN) reported medical — revenue of $309.34K in Q2 2026.

How has Kopin's medical — revenue changed year-over-year?

Kopin's medical — revenue increased by 45.0% year-over-year, from $213.38K to $309.34K.

What does medical — revenue mean?

This metric represents the total gross revenue generated from the sale of optical solutions, microdisplays, and related subassemblies specifically tailored for medical applications. It reflects the commercial traction and market adoption of the company's technology within the healthcare and medical device sectors. Growth in this figure indicates successful expansion into specialized non-military markets and diversification of the company's product portfolio.

Kopin (KOPN) Medical — Revenue

Screener

Other product segments

ASC Six Zero Six Revenues

$9.86M—

Net Product Revenue

$7.64M—

Defense

$7.31M+17.5%

Non ASC Six Zero Six Revenues

$2.87M—

Grant

$2.6M—

Research And Development

$2.17M+139%

Collaboration

$271.48K—

Other Product

$78K-75.6%

License And Royalties

$56K+15.4%

Consumer And Other Product

$50.16K—

Industrial

$20.4K-98.0%

Similar metrics at other companies

ALNTMedical — Revenue

$19.47M+1.9%

THRMMedical — Revenue

$11.35M+1.0%

SLPMedical Communications — Revenue

$2.03M+622%

AEISIndustrial And Medical — Revenue

$72M+12.0%

TTMIMedical Industrial Instrumentation — Revenue

$148.08M+32.7%

CGCCanadian Medical Cannabis — Revenue

$3M+24.1%

Other financials

Income statement

See full

Revenue$12.7M+50.6%

Operating income-$3.5M+35.8%

Net income$830.9K+116%

EPS (diluted)$0.00+100%

Balance sheet

See full

Cash & equivalents$24.9M+2.1%

Total debt$1.2M-47.2%

Total equity$69.2M+331%

Total assets$106.3M+73.7%

Cash flow

See full

Operating cash flow-$4.3M-4.2%

CapEx$3.8M+420%

Free cash flow-$8.1M-66.4%

Valuation

See full

Market cap$791.24M+170%

Enterprise value$767.52M+184%

P/E99.3×—

P/S18.1×+11.9×

Profitability

See full

Gross margin46.7%—

Operating margin-22.9%-4.6pp

Net margin18.3%+11.3pp

FCF margin-42.2%+7.0pp

Returns & leverage

See full

Return on equity18.7%—

Debt / equity0×-0.1×

Current ratio2.2×+0.9×

Where this comes from

Reported directly by Kopin in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Kopin’s 10-Q, filed August 11, 2026.

Filed: Aug 11, 2026, 5:23 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001493152-26-037194

Line item	Three Months Ended June 27, 2026	Three Months Ended June 28, 2025	Six Months Ended June 27, 2026	Six Months Ended June 28, 2025
Grant income	2,598,546	—	6,040,241	—
Collaboration arrangement income	271,478	—	601,089	—
License and other revenues	55,998	48,540	120,926	120,480
Total revenues	12,734,434	8,454,883	23,285,804	18,993,375
Expenses:
Cost of product revenues	6,587,365	7,071,517	12,196,620	14,700,984
Research and development – Funded	3,326,842	463,978	7,133,074	1,102,697
Research and development – Internal	1,197,238	1,481,458	2,302,573	2,958,660

Document

FAQ

What is Kopin's medical — revenue?: Kopin (KOPN) reported medical — revenue of $309.34K in Q2 2026.
How has Kopin's medical — revenue changed year-over-year?: Kopin's medical — revenue increased by 45.0% year-over-year, from $213.38K to $309.34K.
What does medical — revenue mean?: This metric represents the total gross revenue generated from the sale of optical solutions, microdisplays, and related subassemblies specifically tailored for medical applications. It reflects the commercial traction and market adoption of the company's technology within the healthcare and medical device sectors. Growth in this figure indicates successful expansion into specialized non-military markets and diversification of the company's product portfolio.